Abstract
Erectile dysfunction occurs extensively among patients with arterial hypertension. We investigated the safety of sildenafil for patients with and without antihypertensive medication. Our study included data from 35 double-blind, placebo- controlled, and randomized investigations, with a total of 8115 patients. The term of therapy was between 6 weeks and 6 months, for both the sildenafil group (5-200 mg, n = 4819) as well as the placebo group (n = 3296). We studied the adverse events in the men who received 1 or more hypertensives (n = 2388), and in those who took no antihypertensive medication (n = 5727). Our findings disclosed equal frequency of adverse events in both groups, without influence by the number of different antihypertensives administered. The occurrence of AEs associated with blood pressure was slight, and was comparable between the individual groups. These results support the conclusion that sildenafil is also well tolerated by patients taking one or more antihypertensives. Patients being treated with alpha blockers should be stable on this therapy in order to minimize the possibility of orthostatic hypotension. An initial dose of 25 mg should furthermore be considered for these patients.
Keywords: endothelium, antihypertensives, nitric oxide, c-GMP, hypotonsion
Current Drug Safety
Title: Sildenafil is Well Tolerated by Erectile Dysfunction Patients Taking Antihypertensive Medications, Including Those on Multidrug Regimens
Volume: 2 Issue: 1
Author(s): Marko Bohm, Martin Burkart and Gert Baumann
Affiliation:
Keywords: endothelium, antihypertensives, nitric oxide, c-GMP, hypotonsion
Abstract: Erectile dysfunction occurs extensively among patients with arterial hypertension. We investigated the safety of sildenafil for patients with and without antihypertensive medication. Our study included data from 35 double-blind, placebo- controlled, and randomized investigations, with a total of 8115 patients. The term of therapy was between 6 weeks and 6 months, for both the sildenafil group (5-200 mg, n = 4819) as well as the placebo group (n = 3296). We studied the adverse events in the men who received 1 or more hypertensives (n = 2388), and in those who took no antihypertensive medication (n = 5727). Our findings disclosed equal frequency of adverse events in both groups, without influence by the number of different antihypertensives administered. The occurrence of AEs associated with blood pressure was slight, and was comparable between the individual groups. These results support the conclusion that sildenafil is also well tolerated by patients taking one or more antihypertensives. Patients being treated with alpha blockers should be stable on this therapy in order to minimize the possibility of orthostatic hypotension. An initial dose of 25 mg should furthermore be considered for these patients.
Export Options
About this article
Cite this article as:
Bohm Marko, Burkart Martin and Baumann Gert, Sildenafil is Well Tolerated by Erectile Dysfunction Patients Taking Antihypertensive Medications, Including Those on Multidrug Regimens, Current Drug Safety 2007; 2 (1) . https://dx.doi.org/10.2174/157488607779315462
DOI https://dx.doi.org/10.2174/157488607779315462 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PDE-5 Inhibitors: Clinical Points
Current Drug Targets The Relationship Between 24-Hour Indicators and Mortality in Patients with Exertional Heat Stroke
Endocrine, Metabolic & Immune Disorders - Drug Targets Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy Organosulphur Compounds Induce Apoptosis and Cell Cycle Arrest in Cervical Cancer Cells via Downregulation of HPV E6 and E7 Oncogenes
Anti-Cancer Agents in Medicinal Chemistry Peripartum Cardiomyopathy: An Intriguing Challenge. Case Report with Literature Review
Current Cardiology Reviews Binary Actin-ADP-Ribosylating Toxins and their Use as Molecular Trojan Horses for Drug Delivery into Eukaryotic Cells
Current Medicinal Chemistry Nutraceuticals for Promoting Longevity
Current Nutraceuticals Healthy Properties of Garlic
Current Nutrition & Food Science Prodrug Strategies for Antihypertensives
Current Topics in Medicinal Chemistry Diagnosis and Treatment of Paraneoplastic Neurological Syndromes
Current Clinical Pharmacology Impact of Clozapine, N-Desmethylclozapine and Chlorpromazine on Thromboxane Production in Vitro
Medicinal Chemistry Hybrid Stress Testing by Adenosine Infusion and Exercise Myocardial Perfusion Imaging: A Critical Appraisal
Current Cardiology Reviews Serotonin – Kynurenine Hypothesis of Depression: Historical Overview and Recent Developments
Current Drug Targets Pharmacological Targets for the Inhibition of Neurogenic Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Angiotensin Converting Enzyme Inhibitory Peptides Derived from Food Proteins: Biochemistry, Bioactivity and Production
Current Pharmaceutical Design Natural or Plant Products for the Treatment of Neurological Disorders: Current Knowledge
Current Drug Metabolism Endothelin Receptor Antagonists: Another Potential Alternative for Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders Anti-Shock Garments for Obstetric Hemorrhage
Current Women`s Health Reviews Editorial: Pharmacological Therapy to Prevent Sudden Cardiac Death: Indications and Limitations in the Era of Devices
Mini-Reviews in Medicinal Chemistry ALDH2---The Genetic Polymorphism and Enzymatic Activity Regulation: Their Epidemiologic and Clinical Implications
Current Drug Targets